ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The role of metabolites and metabolomics in clinically applicable biomarkers of disease

Mamas, Mamas; Dunn, Warwick B.; Neyses, Ludwig; Goodacre, Royston*
Archives of Toxicology2011-1DOI: 10.1007/s00204-010-0609-6
275被引2阅读
引用收藏
分享

摘要

Metabolomics allows the simultaneous and relative quantification of thousands of different metabolites within a given sample using sensitive and specifc methodologies such as gas or liquid chromatography coupled to mass spectrometry, typically in discovery phases of studies. Biomarkers are biological characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathological processes or pharmacologic responses to a therapeutic intervention. Biomarkers are widely used in clinical practice for the diagnosis, assessment of severity and response to therapy in a number of clinical disease states. In human studies, metabolomics has been applied to define biomarkers related to prognosis or diagnosis of a disease or drug toxicity/efficacy and in doing so hopes to provide greater pathophysiological understanding of disease or therapeutic toxicity/efficacy. This review discusses the application of metabolomics in the discovery and subsequent application of biomarkers in the diagnosis and management of inborn errors of metabolism, cardiovascular disease and cancer. We critically appraise how novel biomarkers discovered through metabolomic analysis may be utilized in future clinical practice by addressing the following three fundamental questions: (1) Can the clinician measure them? (2) Do they add new information? (3) Do they help the clinician to manage patients? Although a number of novel biomarkers have been discovered through metabolomic studies of human diseases in the last decade, none have currently made the transition to routine use in clinical practice. Metabolites identified from these early studies will need to form the basis of larger, prospective, externally validated studies in clinical cohorts for their future use as biomarkers. At this stage, the absolute quantification of these biomarkers will need to be assessed epidemiologically, as will the ultimate deployment in the clinic via routine biochemistry, dip stick or similar rapid at-or near-patient care technologies.

学科与关键词

关键词
MetabolomicsBiomarkersSystems biology
相关
加载中…
  • Metabolomics toward personalized medicine
    Jacob, Minnie; Lopata, Andreas L.; Dasouki, Majed; Rahman, Anas M. Abdel*Mass Spectrometry Reviews, 2019, 38(3): 221-238.被引 236
  • Small molecule metabolites: discovery of biomarkers and therapeutic targets
    Qiu, Shi; Cai, Ying; Yao, Hong; Lin, Chunsheng; Xie, Yiqiang*; Tang, Songqi*; Zhang, Aihua*Signal Transduction and Targeted Therapy, 2023, 8(1): 132.被引 38
  • Use of genome-wide high-throughput technologies in biomarker development
    Classen, Sabine; Staratschek-Jox, Andrea; Schultze, Joachim L.*Biomarkers in Medicine, 2008, 2(5): 509-523.被引 9
查看全部 →

发表信息

论文状态
公开发表
期刊
Archives of Toxicology
发表日期
2011-01
卷期
第 85 卷, 第 1 期
页码
5-17
DOI
10.1007/s00204-010-0609-6
语言
ENGLISH
成果收录
SCIE
资助标注
NIHR Manchester Biomedical Research Centre; The Manchester Academy Health Sciences Centre; The Manchester Centre for Integrative Systems Biology [BB/C008219]; MRC [MC_qA137293] Funding Source: UKRI

作者

  • M

    Mamas, Mamas (第一作者)

  • D

    Dunn, Warwick B.

查看全部 4 位作者收起作者
  • N

    Neyses, Ludwig

  • G

    Goodacre, Royston (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417